In the papers by Bohm et al 1 and Dulai et al, 2 the following grant support statement was omitted: “This study was supported by the UCSD Gastroenterology T32 training grant (DK 0070202).” The authors apologise for this omission.
REFERENCES
- 1. Bohm M, Xu R, Zhang Y, et al; the VICTORY Collaboration . Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Aliment Pharmacol Ther. 2020;52:669‐681. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Dulai PS, Amiot A, Peyrin‐Biroulet L, et al; on Behalf of the GETAID OBSERV‐IBD, VICTORY Cohorts Collaboration . A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2020;51:553‐564. [DOI] [PMC free article] [PubMed] [Google Scholar]